Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Supplements & Reports
|
People
|
Events
|
Multimedia
|
Science Abstracts
|
Scrip   
US panel sees no major cardiovascular risk with saxagliptin
02 April 2009
Sue Sutter

Bristol-Myers Squibb/ AstraZeneca's investigational diabetes agent Onglyza (saxagliptin) does not pose an unacceptable cardiovascular risk, but the companies should nevertheless conduct a large post-approval CV safety study of the DPP-4 inhibitor, the US FDA's outside experts say.

In...



Please Login to read the full article.
 
Not a subscriber? Request a FREE Trial Subscribe to Scrip
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis Other Informa Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Scrip Features Other Informa Features
SCIENCE
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm